Interestingly, TRIM29 overexpression has also been demonstrated to resensitize an oxaliplatin-resistant CRC cell line [94], although, given this was related to TP53 mutant status, of which the TRIM29 protein is not dependent [95] and which is less commonly observed in RCRC [34, 38], further research is necessary to confirm this phenomenon in TP53 wildtype tumors. This evidence concerns the gene TRIM29 and colorectal carcinoma.